Literature DB >> 22592930

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.

Rita Golfieri1, Luigi Grazioli, Emanuela Orlando, Ada Dormi, Vincenzo Lucidi, Beniamino Corcioni, Ernesto Dettori, Laura Romanini, Matteo Renzulli.   

Abstract

PURPOSE: To investigate whether the malignancy of atypical nodules in cirrhosis can be identified at gadoxetic-acid-disodium(Gd-EOB-DTPA)-MRI by their hypointensity in the hepatobiliary(HB)-phase alone or combined with any other MR imaging features.
MATERIALS AND METHODS: One hundred eleven atypical nodules detected in 77 consecutive Gd-EOB-DTPA-MRIs were divided, based on arterial-phase behavior, into: Class I, isovascular (n = 82), and Class II, hypervascular without portal/delayed washout (n = 29). The two classes were further grouped based on HB-phase intensity (A/B/C hypo/iso/hyperintensity). Portal/venous/equilibrium-phase behavior and T2w features were also collected. Histology was the gold standard. Per-nodule sensitivity, specificity, negative and positive predictive values (NPV/PPV), and diagnostic accuracy were calculated for HB-phase hypointensity alone, and combined with vascular patterns and T2w hyperintensity.
RESULTS: Histology detected 60 benign and 51 malignant/premalignant nodules [10 overt hepatocellular carcinomas (HCCs) and 41 high-grade dysplastic nodules (HGDN)/early HCC]. Class IA contained 31 (94%) malignancies, IB one (3%), and IC only benign lesions. Class IIA had 100% malignancies, IIB three (37.5%) and IIC only two (28.5%). HB-phase hypointensity alone (Classes I-IIA) had 88% sensitivity, 91% NPV, and 93% diagnostic accuracy, superior (P < 0.05, P < 0.006, and P < 0.05, respectively) to any other MR imaging feature alone or combined.
CONCLUSION: In atypical cirrhotic nodules, HB-phase hypointensity by itself is the strongest marker of malignancy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592930     DOI: 10.1002/jmri.23685

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  31 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

3.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?

Authors:  Massimo Galia; Adele Taibbi; Daniele Marin; Alessandro Furlan; Marco Dioguardi Burgio; Francesco Agnello; Giuseppe Cabibbo; Bernard E Van Beers; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

6.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

Review 7.  Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions.

Authors:  Andrea Agostini; Moritz F Kircher; Richard K G Do; Alessandra Borgheresi; Serena Monti; Andrea Giovagnoni; Lorenzo Mannelli
Journal:  Semin Roentgenol       Date:  2016-05-30       Impact factor: 0.800

8.  Respiratory Motion-Resolved Compressed Sensing Reconstruction of Free-Breathing Radial Acquisition for Dynamic Liver Magnetic Resonance Imaging.

Authors:  Hersh Chandarana; Li Feng; Justin Ream; Annie Wang; James S Babb; Kai Tobias Block; Daniel K Sodickson; Ricardo Otazo
Journal:  Invest Radiol       Date:  2015-11       Impact factor: 6.016

9.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

10.  Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Authors:  Elsa Iannicelli; Marco Di Pietropaolo; Massimo Marignani; Chiara Briani; Giulia Francesca Federici; Gianfranco Delle Fave; Vincenzo David
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.